Director TitleAgeSince
Director/Board Member - 2010-09-30
Director/Board Member - 2010-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+179,900.00%-14.29% - - 172K
-0.49%+1.53%+13.55%+82.58% 48.11B
-1.41%+5.55%+70.04%+116.16% 37.88B
-1.39%-0.16%-4.06%+42.16% 12.47B
+0.44%+2.83%+15.18%+96.06% 12B
+1.82%+2.76%+34.19%+120.25% 9.03B
-0.16%+1.91%+22.31%+47.95% 7.24B
+0.41%+2.01%+55.16%-3.74% 7.09B
-2.81%+17.66%-18.38%+20.93% 6.54B
-0.26%+3.58%+23.74%+238.93% 6.72B
Average +17,989.62%+4.16%+23.52%+84.59% 16.34B
Weighted average by Cap. -0.40%+3.97%+29.49%+89.75%
Logo Pivotal Therapeutics Inc.
Pivotal Therapeutics Inc is a Canada-based specialty pharmaceutical company with a focus on optimizing Omega-3 therapy for cardiovascular disease and overall health. The Company's lead product VASCAZEN is used to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase in high-density lipoprotein- Cholesterol (HDL-C) without a negative impact on the low density lipoprotein cholesterol (LDL-C) lipid profile. Its second product, OMAZEN is a greater than 90% pure, pharmaceutical grade Omega-3 commercialized for sale and distribution in Canada only for the maintenance of health.
Employees
-
  1. Stock Market
  2. Stocks
  3. PVTTF Stock